DUBLIN – Boehringer Ingelheim GmbH is bringing another drug mechanism to bear on nonalcoholic steatohepatitis (NASH), by exercising an option to in-license PXS4728A, a dual semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) inhibitor from Pharmaxis Ltd. for €27.5 million (US$31.4 million) up front with about $570 million more to come in milestones.